COVID-19 vaccine developers little changed on news of Trump/First Lady infection

• Investors in COVID-19 vaccine and therapy developers appear unmoved with the news that President Trump and First Lady Melania have both tested positive for the respiratory infection and will begin quarantine immediately.
• Selected tickers: Sanofi (NASDAQ:SNY) (-1%), GlaxoSmithKline (NYSE:GSK) (up a fraction), AstraZeneca (NASDAQ:AZN) (up a fraction), Merck (NYSE:MRK) (down a fraction), Johnson & Johnson (NYSE:JNJ) (-1%), Moderna (NASDAQ:MRNA) (-1%), Pfizer (NYSE:PFE) (-1%), BioNTech SE (NASDAQ:BNTX) (+1%), Dynavax (NASDAQ:DVAX) (-2%), Novavax (NASDAQ:NVAX) (-1%), Gilead Sciences (NASDAQ:GILD) (up a fraction), Eli Lilly (NYSE:LLY) (-1%); Regeneron Pharmaceuticals (NASDAQ:REGN) (-1%)
• https://seekingalpha.com/news/3619371-covidminus-19-vaccine-developers-little-changed-on-news-of-trump-first-lady-infection